Trial Profile

A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination With Nivolumab or Standard of Care in Patients With Locally Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Osemitamab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
Indications Cholangiocarcinoma; Colon cancer; Gastric cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms TransStar101
Sponsors MabSpace Biosciences

13 Apr 2025 Planned End Date changed from 31 Dec 2024 to 30 Sep 2025.
13 Apr 2025 Planned primary completion date changed from 30 Nov 2024 to 30 May 2025.
18 Oct 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Nov 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com